MedTrace Logo

Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma

NCT05289492 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2024-10-26

No results posted yet for this study

Summary

This is a multicenter, open-label, phase I/II clinical study, to assess the safety, tolerability, antitumor activity, pharmacokinetics and pharmacodynamics of EOS884448 (also known as EOS-448 or GSK4428859A), alone or in combination with iberdomide with and without dexamethasone in participants with relapsed/refractory multiple myeloma (RRMM).

Conditions

Interventions

DRUG

EOS884448

EOS884448 will be administered in arm A,B and C

DRUG

Iberdomide

Iberdomide will be administered in arm B and C

DRUG

Dexamethasone

Dexamethasone will be administered in arm C

Sponsors & Collaborators

Principal Investigators

  • Iteos Clinical Trials · iTeos Belgium SA

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2023-11-29
Completion
2023-11-29
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • France
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05289492 on ClinicalTrials.gov